A Netherlands-based company with new technology for antibody-drug conjugates (ADC) announced the completion of a $65 million Series A financing on 22 June. Tagworks Pharmaceuticals BV was founded in 2011 and currently has one preclinical ADC in development and four in discovery. The financing will enable it to advance the lead programme, TGW101, and test a new concept in oncology drug development.
